Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer-Reference-Cited by-同舟云学术

Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer

Published:2023-12 Issue:6 Volume:115 Page:292-301
ISSN:1591-951X
Container-title:Pathologica
language:
Short-container-title:Pathologica

Author:

Marchiò Caterina,Criscitiello Carmen,Scatena Cristian,Santinelli Alfredo,Graziano Paolo,Malapelle Umberto,Cursano Giulia,Venetis Konstantinos,Fanelli Giuseppe Nicolò,Pepe Francesco,Berrino Enrico,De Angelis Carmine,Perrone Giuseppe,Curigliano Giuseppe,Fusco Nicola

Publisher

Siapec Servizi Srl

Reference74 articles.

1. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. J Clin Oncol 2022;40(17_suppl):LBA3-LBA3. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA3

2. Mosele F, Deluche E, Lusque A, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med 2023;29(8):2110-2120. https://doi.org/10.1038/s41591-023-02478-2

3. Nicolò E, Boscolo Bielo L, Curigliano G, et al. The HER2-low revolution in breast oncology: steps forward and emerging challenges. Ther Adv Med Oncol 2023;15:17588359231152842. https://doi.org/10.1177/17588359231152842

4. Venetis K, Crimini E, Sajjadi E, et al. HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Front Mol Biosci 2022a;9:834651. https://doi.org/10.3389/fmolb.2022.834651

5. Schlam I, Tolaney SM, & Tarantino P How I treat HER2-low advanced breast cancer. Breast 2023;67:116-123. https://doi.org/10.1016/j.breast.2023.01.005

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AI's role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy;Intelligent Pharmacy;2024-08

2. Healthcare Systems and Artificial Intelligence: Focus on Challenges and the International Regulatory Framework;Pharmaceutical Research;2024-03-05

3. HER2-Low Expression in Male Breast Cancer: Results from a Multicenter Series in Italy;Cancers;2024-01-27